AI assistant
Teva Pharmaceutical Industries Ltd. — AGM Information 2015
Oct 1, 2015
7082_rns_2015-10-01_2d5eb2f4-77e3-4b1e-b552-104d2325c26f.htm
AGM Information
Open in viewerOpens in your device viewer
convening of meeting false
C460��� ������ ��������� ��"�2PublicTEVA- PHARMACEUTICAL INDUSTRIES LTD10817Corporation no: 520013954Stock Exchange/Market: NYSE310670P.O.B 3190 , Petach Tikva 49131 , ,Tel: 03-9267267 , 03-9267652 Fax: 03-9267519E.mail address: [email protected] via MAGNA: 01/10/2015 Time of broadcast: 23:36 23:33:45
Reference: 2015-02-127344
| Israel Securities Authority | Tel Aviv Stock Exchange | |||||
| www.isa.gov.il | www.tase.co.il |
_________Immediate Report of MeetingRegulation 36B (a) and (d) of the Securities Regulations (Periodic and Immediate Reports), 5730-1970
Explanation: This form is to be used only by companies which are subject to the Israeli Companies Law 5759-1999
| The corporation hereby gives notice of: | convening of meeting |
The reference number for the most recent notification of a meeting is _________ which was called for the date _________
| Reason for Postponement or Cancellation: | _________ | _________ |
Explanation: Please refer to the reference number of the most recent notification of the convening or deferral of the meeting
1. On the date: 25/09/2015it was decided on convening of meeting extraordinary meeting _________ ,that will be held on the day Thursday on the date : 05/11/2015 time: 16:30
| at address: | Teva's executive offices at 5 Basel Street, Petach Tikva, Israel |
2. Details of security in the Stock Exchange that entitles the holder thereof to participate in the meetingSecurity number 629014Security name ���Security type ShareExplanation: If a meeting concerning more than one security is required, a report on C460 will be made separately for every additional security. Reports that specify additional security numbers must be followed by an amending reportThe determining date for entitlement to participate and vote in the meeting: 06/10/2015
3. On the Agenda - Items/Decisions to be raised at the meeting11The item/decision and its particulars:Approval of the creation of a new class of Mandatory Convertible Preferred Shares, nominal (par) value NIS 0.1 per share and the definition of their terms, and certain related amendments to Teva�s Articles of Association and Memorandum of Association.
Declaration: There is no field appropriate to the classificationReference concerning the last report concerning the matter of a private placement (if it exists) _________
No Transaction between the company and the controlling shareholder under section 275 and 320 (f) of the Companies Law.Reference concerning the last report on the item (if it exists) _________
Amendment of disclosure
An unimportant change or a change that solely credits the company comparing to the previous version of the decision, as detailed at the last report.
No longer on the agenda
item was discussed at previous meeting
Items brought for one of the following: Voting
| Majority required not a simpe majority | 75% of the participating and voting ordinary shares (as described in the proxy statement) |
Attachment of report of convening meeting: 2015_Special_Meeting_Proxy_Statement_-_FINAL_isa.pdf
4. AttachedYes wording of the voting letterNo position notification2015_SGM_HEBREW_Voting_Card_-_FOR_MAGNA_isa.pdf
No declaration of candidate to serve as director in corporation.No declaration of independent directorNo declaration of outside director_________
5. The place and the times at which it is possible to examine any proposed decision the wording of which was not presented in full in the specification of the agenda aboveMay be viewed at Teva's website at www.tevapharm.com, through the EDGAR at www.sec.gov, or through the Israeli Securities Authority electronic filing system at www.magna.isa.gov.il.
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): |
| Previous names of reporting entity: |
| Date of revision of form structure: 16/09/2015 |
| - - - |
| Name of the Signatory: : Beck Codner Iris , Position of Signatory in the reporting corporation: Vice President, Global Corporate Communication , Name of Employer Company: . |
| Basel Telephone: 03-9267208 , Facsimile: 03-9267851 , E-mail: [email protected] 1 |